E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Crohn's Disease Ulcerative Colitis Rheumatoid Arthritis Psoriatic Arthritis Ankylosing Spondylitis |
|
E.1.1.1 | Medical condition in easily understood language |
Inflammation and /or ulceration of the gut Inflammation of the joints and /or spine |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Immune System Diseases [C20] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
This research is evaluating the outcome of switching patients with Ulcerative Colitis (UC), Crohn’s Disease (CD), Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) and Ankylosis Spondylitis (AS) who are currently treated with intravenous (IV) infliximab to a subcutaneous preparation of infliximab (CT-P13, a biocoimlar of infliximab). Patients in most cases will be already treated with a biosimilar infliximab intravenously such as SB2 (Flixabi) or the intravenous version of CT-P13.
A biosimilar drug means it is highly similar to the brand (originator) product but made in a slightly different way. This leads to tiny differences, but should not affect how the drug works, or it’s safety and side effects. Participants will be switched from the originator or reference drug infliximab (Remicade) to CT-P13 (Remsima)
Changing the mode of delivery of a drug from intravenous to subcutaneous may lead to an increase in the serum drug levels of infliximab, which is often associated with bette |
|
E.2.2 | Secondary objectives of the trial |
•How safe and tolerable is it to change the the mode of delivery from intravenous to subcutaneous •Evaluate the drug levels of infliximab in the blood •Standard markers of inflammatory through the study •Gather information regarding any impact on the quality of life patients through this process •Gather information on subject experience and treatment satisfaction over time |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
-Subjects with the following characteristics are eligible for this study: -Confirmed diagnosis of Crohn's Disease, Ulcerative colitis, Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosis Spondylitis -Established on IV infliximab (>4 doses) prior to study enrolment -Anticipated to remain on infliximab for the duration of the study -Last dose of IV infliximab received < 8 weeks ago -Able to comply with study requirements -Able to provide informed consent ≥18 years and over
|
|
E.4 | Principal exclusion criteria |
-Allergic to any of the known excipients of infliximab -Scheduled for a surgical procedure or planned hospitalisation within 6 months of enrolment -Not anticipated to remain on infliximab for more than 6 months after enrolment -Pregnant or lactating women -Unable to comply with study requirements -Unable to provide informed consent <18 years
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary outcome measurement of this study is the proportion of subjects maintaining baseline clinical status at week 24.
This will be assessed by disease specific activity scores calculated at baseline and 24 weeks.
• Modified Harvey-Bradshaw index (mHBI) for CD patients • Simple Clinical Colitis Activity Index (SCCAI) score for UC patients • Inflammatory Bowel Disease-Control (IBD-CTRL) for IBD patients • Disease Activity Score (DAS-28/CDAI) for RA and PsA patients • Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) for AS patients. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
•How safe it is to switch from the originator drug to a biosimilar drug •How safe and tolerable is it to change the the mode of delivery from intravenous administration to a sub-cutaneous injection. •Evaluate the drug levels of CT-P13 in the blood and evaluate immunogenicity •How the immune system responds to this change by looking at inflammatory markers over time •Gather information regarding the quality of life over time •Gather information on subject experience and treatment satisfaction over time
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
|
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of trial will be defined as the last patient's last visit at week 24 for participants. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 5 |
E.8.9.1 | In the Member State concerned days | 31 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 5 |
E.8.9.2 | In all countries concerned by the trial days | 31 |